Cabozantinib

Generic Name: Cabozantinib

Brand Names: Cabometyx, Cometriq

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₄FN_₃O_₅

CAS Number: 849217-68-1

Unique Ingredient Identifier: 1C39JW444G

Background: Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...

Indication: ⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。

⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。

Associated Conditions: Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2

Conditions: Rare Tumor
Refractory Tumor

Interventions: Drug: Gefitinib
Drug: Erlotinib
Drug: Afatinib
Drug: Trastuzumab
Drug: Oxazolidine
Drug: Olaparib
Drug: Everolimus
Drug: Cabozantinib
Drug: Vemurafenib
Drug: Dabrafenib
Drug: Palbociclib
Drug: PD-1/L1 inhibitor plus anti-angiogenic agent

First Posted Date: 2017-08-03

Last Posted Date: 2022-03-04

Lead Sponsor: Baodong Qin

Target Recruit Count: 300

Registration Number: NCT03239015

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Cabozantinib

First Posted Date: 2017-06-28

Last Posted Date: 2023-09-08

Lead Sponsor: University of Nebraska

Target Recruit Count: 11

Registration Number: NCT03201250

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Avelumab
Drug: Cabozantinib

First Posted Date: 2017-06-27

Last Posted Date: 2024-07-03

Lead Sponsor: University of Utah

Target Recruit Count: 12

Registration Number: NCT03200587

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Endometrial Cancer
Gastric Cancer
Renal Cell Carcinoma
Castration-resistant Prostate Cancer
Colorectal Cancer
Differentiated Thyroid Cancer
Ovarian Cancer
Lower Esophageal Cancer
Urothelial Carcinoma

Interventions: Drug: atezolizumab
Drug: cabozantinib

First Posted Date: 2017-05-31

Last Posted Date: 2023-07-27

Lead Sponsor: Exelixis

Target Recruit Count: 1732

Registration Number: NCT03170960

Locations: 🇺🇸
Exelixis Clinical Site #51, Newport Beach, California, United States
🇪🇸
Exelixis Clinical Site #94, Oviedo, Asturias, Spain
🇺🇸
Exelixis Clinical Site #10, Boston, Massachusetts, United States

and more 121 locations

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Phase 1

Active, not recruiting

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Cabozantinib
Drug: Pembrolizumab

First Posted Date: 2017-05-11

Last Posted Date: 2024-02-06

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 45

Registration Number: NCT03149822

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
🇺🇸
Memorial Hospital Central, Colorado Springs, Colorado, United States

and more 2 locations

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Sunitinib
Drug: Cabozantinib

First Posted Date: 2017-05-04

Last Posted Date: 2024-01-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 701

Registration Number: NCT03141177

Locations: 🇪🇸
Local Institution - 0125, Barcelona, Spain
🇪🇸
Local Institution - 0121, Madrid, Spain
🇦🇺
Local Institution - 0001, Southport, Queensland, Australia

and more 132 locations

The Drug Rediscovery Protocol (DRUP Trial)

First Posted Date: 2016-10-05

Last Posted Date: 2024-01-24

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 1550

Registration Number: NCT02925234

Locations: 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱
Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

and more 33 locations

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Phase 2

Terminated

Conditions: Glioblastoma Multiforme
Malignant Brain Tumor
High Grade Glioma
Anaplastic Astrocytoma

Interventions: Drug: Cabozantinib

First Posted Date: 2016-08-31

Last Posted Date: 2022-10-06

Lead Sponsor: Indiana University

Target Recruit Count: 4

Registration Number: NCT02885324

Locations: 🇺🇸
Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2

Active, not recruiting

Conditions: Recurrent Adrenal Cortical Carcinoma
Recurrent Clear Cell Sarcoma of Soft Tissue
Recurrent Ewing Sarcoma
Recurrent Osteosarcoma
Recurrent Primary Malignant Central Nervous System Neoplasm
Recurrent Renal Cell Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Wilms Tumor
Alveolar Soft Part Sarcoma
Central Nervous System Neoplasm

Interventions: Drug: Cabozantinib
Drug: Cabozantinib S-malate
Other: Pharmacological Study

First Posted Date: 2016-08-16

Last Posted Date: 2024-10-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 109

Registration Number: NCT02867592

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸
Kaiser Permanente-Bellflower, Bellflower, California, United States

and more 140 locations

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2

Completed

Conditions: Urothelial Carcinoma
Gastrointestinal Carcinoma, Non-colon
Upper Aerodigestive Tract Carcinoma
Non-small Cell Lung Carcinoma

Interventions: Drug: Afatinib
Drug: Regorafenib
Drug: Cabozantinib

First Posted Date: 2016-06-09

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 100

Registration Number: NCT02795156

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists - East, West Palm Beach, Florida, United States

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy